Incidence, Predictors, and Results of Acute Kidney Injury in Patients Undergoing TAVR

Acute kidney injury after transcatheter aortic valve replacement (TAVR) is a well-known adverse event for all interventional cardiologists. However, it has been understudied: only small observational research has been conducted, showing too wide incidence rates.

Incidencia, predictores y resultados de la injuria renal aguda en pacientes que reciben TAVI

This research included all patients who underwent TAVR in the USA between 2016 and 2018, totaling over 100,000 patients. All subjects had creatinine analysis done at baseline and after the procedure. Patients in hemodialysis were excluded.

A total of 11,566 patients (10.7%) suffered kidney injury after the procedure. The vast majority had grade 1 impairment, some presented grade 2, and 1212 (1.1% of the general population) had grade 3 injury.

Clinical factors associated with grade 3 (severe) kidney injury were high levels of creatinine, diabetes, cardiogenic shock, peripheral vascular disease, severe anemia, and African American heritage.

The procedural characteristics associated with grade 3 injury were non-elective procedure, crossover to conventional surgery, general anesthesia, use of inotropic drugs, use of self-expandable prosthesis, and contrast volume >100 milliliters.


Read also: Back to Basics: Ticagrelor Questioned and Clopidogrel in the Limelight.


Mortality at one year among those who developed grade 1 kidney injury almost tripled that of those without kidney injury (hazard ratio [HR]: 2.7; 95% confidence interval [CI]: 2.5-2.8; p < 0.001), and in those with grade 3 injury, mortality was 7 times higher (HR: 7; 95% CI: 6.0-8.2; p < 0.001).

Conclusion

Using the STS/ACC database, acute kidney injury after TAVR has a 10.7% prevalence. Patients with grade 3 injury present 7x higher risk of one-year mortality than those without renal impairment.

Original title: Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement.

Reference: Howard M Julien et al. Circ Cardiovasc Interv. 2021 Apr;14(4):e010032. Doi: 10.1161/CIRCINTERVENTIONS.120.010032.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...